$XBI $92.94 | -0.33%
Covid Updates
$NVAX -12.0% Novavax falls short of COVID-19 vaccine deliveries - Reuters. source
$IMNM -4.3% Immunome’s Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in In Vitro Live Virus Testing. source
Pipeline Updates
$EOLS +7.1% Evolus Receives Acceptance of Submission in Australia, a Pivotal Step in Approval Process for Nuceiva®. source
$EYEN +4.8% Eyenovia Concludes Type A Meeting with FDA Related to MydCombi™ NDA Resubmission. source
$AKRO +0.5% Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients. source
$KPTI -20.0% Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer. source
$CYT +2.5% Cyteir Therapeutics Announces First Patient Dosed in Phase 2 with CYT-0851. source
$ALKS -1.7% Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI® in Patients Early in Illness. source
$SGMO -1.6% Sangamo's gene therapy for Fabry Disease shows safety in interim phase 1/2 trial data. source
$AGTC +7.8% AGTC Announces Robust Improvements in Visual Sensitivity in Adult and Pediatric Patients, and Plans to Continue Clinical Development of AGTC-401 in Patients with CNGB3 Achromatopsia. source
Business Updates
$ZSAN +3.1% Zosano Pharma Announces Proposed Public Offering of Common Stock and Warrants source
$KPTI -20.0% Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress. source
Posted by FS/JM
Comentários